Oncotarget

In The News



GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K


2017-12-06
GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-reviewed articles have been published in the prestigious journal, Oncotarget , elaborating on the anti-tumor activity of GamaMabs’ lead compound GM102/3C23K for ovarian cancer. The studies were performed by GamaMabs ...continue reading >>


Dandelion Root Benefits vs. Dandelion Greens Benefits - Health | Food is Medicine


2017-12-02
Share on Twitter By Rachael Link, MS, RD Dandelions have a reputation as both a granter of wishes and a dreaded weed and lawn nuisance. However, did you know that both dandelion root and dandelion greens are loaded with nutrients and boast a variety of benefits to your health — just like dandelion tea ? Dandelion is low in calories but high in fiber as well as vitamin K, vitamin A and vitamin C . The root and greens have also been shown to have some pretty impressive health benefits and may ...continue reading >>


New method for suppressing lung cancer oncogene


2017-11-30
New method for suppressing lung cancer oncogene November 30, 2017 The artificial transcription factor (ATF) created by Professor Sera and colleagues is capable of suppressing the expression of SOX2 protein, an oncogene associated with both lung and esophageal cancer. Credit: Okayama University Researchers at Okayama University describe in Oncotarget an approach for suppressing the expression of the SOX2 protein, an oncogene associated with both lung and esophageal cancer. The procedure, based o ...continue reading >>


New method for suppressing lung cancer oncogene - Healthcanal.com : Healthcanal.com


2017-11-30
Researchers at Okayama University describe in Oncotarget an approach for suppressing the expression of the SOX2 protein, an oncogene associated with both lung and esophageal cancer. The procedure, based on the targeted delivery of a specially designed artificial protein, may signify an important step towards new cancer therapies. Most cancer-related deaths world-wide are caused by lung cancer. For one type of lung cancer, lung squamous cell carcinoma (SCC), a protein called SOX2 is known t.. Adv


Okayama University research: New method for suppressing lung cancer oncogene


2017-11-29
Okayama University research: New method for suppressing lung cancer oncogene Share Article Researchers at Okayama University describe in Oncotarget an approach for suppressing the expression of the SOX2 protein, an oncogene associated with both lung and esophageal cancer. The procedure, based on the targeted delivery of a specially designed artificial protein, may signify an important step towards new cancer therapies. The artificial transcription factor (ATF) created by Professor Sera and colle ...continue reading >>


Promising Target for Treating Brain Tumors in Children


2017-11-28
Printer friendly page (HealthNewsDigest.com) - Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro . Now, they have demonstrated its success in an animal model – the drug shrank the tumor and increased survival. Importantly, t ...continue reading >>


Promising target for treating brain tumours in children


2017-11-28
Promising target for treating brain tumours in children 28 Nov 2017 Findings published in Oncotarget offer new hope for children with highly aggressive brain tumours like atypical teratoid/rhabdoid tumour (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped paediatric brain tumour growth in vitro. Now, they have demonstrated its success in an animal model - the drug shrank the tumour and increase ...continue reading >>


Promising target for treating brain tumors in children


2017-11-28
Promising target for treating brain tumors in children November 28, 2017 Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro. Now, they have demonstrated its success in an animal model - the drug shrank the tumor and increased ...continue reading >>


A protein indicating higher breast cancer mortality risk


2017-11-20
Healthcare A protein indicating higher breast cancer mortality risk With the support of the FWF, an oncologist found a biomarker for breast cancer having a poor prognosis and developed two viable methods to detect it in tissue samples. (businesspress24) - Breast cancer is the most frequent malignant tumour in women worldwide. In Austria, about 5,500 women develop it each year and 1,500 die of it despite the availability of an early detection programme. When a lump is found in a breast, the next ...continue reading >>


Ein Protein zeigt höhere Brustkrebs-Sterblichkeit


2017-11-20
20.11.2017 | Autor: PR&D Kommunikationsdiensleistungen GmbH Ein Protein zeigt höhere Brustkrebs-Sterblichkeit An der Medizinischen Universität Graz wurde, unterstützt vom Wissenschaftsfonds FWF, ein Biomarker für Brustkrebs mit schlechten Heilungschancen gefunden und gleich zwei praktikable Nachweismethoden für Gewebeproben entwickelt. Brustkrebs ist der häufigste bösartige Tumor bei Frauen weltweit. In Österreich erkranken knapp 5.500 Frauen jährlich an dieser Krebsart und 1.500 sterbe ...continue reading >>


Positive News Coverage Somewhat Unlikely to Impact TRACON Pharmaceuticals (TCON) Share Price


2017-11-15
TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget (finance.yahoo.com) TRACON Pharmaceuticals ( NASDAQ TCON ) remained flat at $$2.80 during mid-day trading on Tuesday. The company had a trading volume of 300,100 shares, compared to its average volume of 98,149. TRACON Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $7.30. The company has a debt-to-eq ...continue reading >>


Converging blockchain and next-generation AI technologies to accelerate biomedical research


2017-11-15
15-Nov-2017 Converging blockchain and next-generation AI technologies to accelerate biomedical research Blockchain and AI researchers propose a new model to return the control over human life data to the patients and accelerate biomedical research InSilico Medicine, Inc. IMAGE: Converging AI and Blockchain technologies help control over human life data to the patients and accelerate biomedical research. view more Credit: Insilico Medicine, Inc. Wednesday, 15th of November, 2017, 10AM EST, Balt ...continue reading >>


Oncotarget: Researchers identify potential therapeutic target in aggressive breast cancer cells


2017-11-15
Oncotarget: Researchers identify potential therapeutic target in aggressive breast cancer cells (Rapamycin Press) An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta, according to research published in Oncotarget. Category: Cancer & Oncology Nipple ‐sparing mastectomy as treatment for patients with ductal carcinoma in situ: A 10‐year follow‐up study The objective was to determine the 10‐year on ...continue reading >>


TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget


2017-11-14
TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget 14 Nov, 2017 Tweet SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive result ...continue reading >>


BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara


2017-11-14
Nov 13 (Reuters) - Tracon Pharmaceuticals Inc: * Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget * Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​ * Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to co ...continue reading >>


TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget


2017-11-14
TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget Overall response rate of 24% seen with no dose limiting toxicity observed November 13, 2017 16:05 ET | Source: TRACON Pharmaceuticals, Inc. SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...continue reading >>


Researchers discover new way to identify antibiotics using cancer cells


2017-11-13
Clinical Pharmacist 13 NOV 2017 Three of the compounds explored in the study inhibited cancer cell growth and also behaved as broad-spectrum antibiotics, with two effective against Staphylococcus aureus A current strand of cancer research is to look for compounds that can inhibit the mitochondria, which are thought to be upregulated in some cancers. Given that mitochondria are thought to have evolved from bacteria, a research team performed in silico and in vitro drug screening to identify ca ...continue reading >>


TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget | 4-Traders


2017-11-13
SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive results from a Phase 1 clinical trial of TRC102 (methoxyamine) and Fludara® (fludarabine) in patients with advanced hematologic malignancies were published in the journal Oncotarget (Volume 8 ...continue reading >>


TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget


2017-11-11
SAN DIEGO, Nov. 13, 2017 ( GLOBE NEWSWIRE) -- TRACON Pharmaceuticals ( NASDAQ : TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive results from a Phase 1



Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC